First-in-Human gene therapy trial targets inherited heart weakness
NCT ID NCT07218887
Summary
This early-stage study is testing a new, one-time gene therapy called ALXN2350 for adults with a specific genetic form of heart muscle disease (BAG3 mutation). The main goals are to find a safe dose and see if the treatment helps control the disease. It will involve a small group of participants who will receive a single infusion and be monitored closely for safety and heart function.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BAG3 MUTATION ASSOCIATED DILATED CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGBirmingham, Alabama, 35233, United States
-
Research Site
RECRUITINGBoston, Massachusetts, 02115, United States
-
Research Site
RECRUITINGCincinnati, Ohio, 45219, United States
-
Research Site
RECRUITINGPortland, Oregon, 97239-3098, United States
-
Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Research Site
RECRUITINGBarcelona, 08035, Spain
-
Research Site
RECRUITINGMajadahonda, 28222, Spain
Conditions
Explore the condition pages connected to this study.